4th November, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on 4th November, 2026

With reference to the captioned matter, the stock exchanges are hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today inter-alia has approved the Consolidated and Standalone Unaudited Financial Results along with the Limited Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended 30th September, 2026.

The time of commencement of Board Meeting was 11:30 a.m. and the time of conclusion was 2:10 p.m.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Chirag K. Shukla
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED * VADODARA 390003.

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED
CIN:L24230GJ2010PLC061123
Regd.Office: Alembic Road, Vadodara - 390 003
Tel : 0265 6537000
Email : apl.investors@alembic.co.in
Website : www.alembicpharmaceuticals.com

Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2026

Rs. in Crores

	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
1	**Revenue from Operations**	**2,603.48**	2,149.77	1,910.15	**4,753.25**	3,620.87	7,344.90
2	Other Income	**15.11**	14.93	6.91	**30.04**	13.41	54.41
3	**Total Income**	**2,618.59**	2,164.70	1,917.06	**4,783.29**	3,634.28	7,399.31
4	Expenses						
	(a) Cost of Materials consumed	**599.64**	517.30	463.14	**1,116.94**	894.41	1,747.38
	(b) Purchase of stock-in-trade	**177.22**	120.50	126.82	**297.73**	235.98	508.88
	(c) Changes in Inventories of finished goods, Stock in trade and WIP	**(91.09)**	(17.72)	(74.04)	**(108.81)**	(207.06)	(271.81)
	(d) Employee benefits expense	**503.75**	473.94	437.54	**977.70**	860.31	1,731.93
	(e) Finance Costs	**38.26**	27.61	24.23	**65.86**	47.75	93.63
	(f) Depreciation & Amortization Expense	**100.80**	97.71	76.07	**198.52**	149.84	318.55
	(g) Other Expenses	**850.69**	723.89	641.00	**1,574.58**	1,240.19	2,510.06
	Total Expenses	**2,179.27**	1,943.23	1,694.76	**4,122.51**	3,221.43	6,638.61
5	**Profit before Share of Profit / (Loss) of Associates and Joint Ventures**	**439.31**	221.47	222.30	**660.79**	412.85	760.69
6	Share of Profit / (Loss) of Associates & Joint Ventures	**(1.37)**	0.39	1.42	**(0.98)**	0.97	0.24
7	**Profit Before Exceptional Item and Tax**	**437.95**	221.86	223.72	**659.81**	413.82	760.94
8	Exceptional Item - Refer Note No. 3	**-**	-	-	**-**	-	(66.99)
9	**Profit Before Tax**	**437.95**	221.86	223.72	**659.81**	413.82	693.95
10	**Tax Expense**						
	(i) Current Tax	**98.67**	44.35	46.59	**143.02**	68.81	127.60
	(ii) Deferred Tax	**5.38**	5.15	(6.59)	**10.52**	7.67	(104.48)
11	**Profit for the Period before non-controlling interests**	**333.91**	172.36	183.71	**506.27**	337.34	670.83
12	Non-controlling interests	**1.26**	0.71	1.00	**1.97**	1.75	3.94
13	**Profit for the Period after non-controlling interests**	**335.17**	173.07	184.71	**508.23**	339.09	674.77
14	**Other Comprehensive Income**						
	A (i) Items that will not be reclassified to profit / (loss)	**(2.69)**	(0.49)	(7.18)	**(3.18)**	(7.65)	(6.96)
	(ii) Income tax relating to items that will not be reclassified to profit / (loss)	**0.68**	0.12	1.25	**0.80**	1.34	0.93
	B (i) Items that will be reclassified to profit / (loss)	**(4.17)**	3.14	10.59	**(1.04)**	11.69	30.89
	(ii) Income tax relating to items that will be reclassified to profit / (loss)	**1.14**	(0.49)	-	**0.65**	-	-
	Total Other Comprehensive Income (A+B)	**(5.05)**	2.28	4.67	(2.77)	5.38	24.86
15	**Total Comprehensive Income for the period (11+14)**	**328.86**	174.63	188.38	**503.50**	342.72	695.69
	Attributable to:						
	- Non-controlling interests	**(1.35)**	(0.70)	(1.10)	**(2.05)**	(1.86)	(4.41)
	- Owners of the Company	**330.21**	175.33	189.49	**505.54**	344.58	700.09
16	Earnings per share - Basic & Diluted (in Rs.)	**17.05**	8.80	9.40	**25.86**	17.25	34.33
17	Paid up Equity Share Capital (Face Value of Rs 2/- each)	**39.31**	39.31	39.31	**39.31**	39.31	39.31
18	Other Equity						5,635.50

kkc & associates llp Chartered Accountants

Notes :

1 The above consolidated results have been recommended by the Audit Committee and approved by the Board of Directors of the Company. The results have been subjected to review by the statutory auditors of the Company. The report of the statutory auditors is unqualified.

2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.

3 Exceptional items for the year ended 31st March 2026 comprised Rs. 48.64 crore relating to employee benefit obligations arising from the revised definition of wages under the Labour Codes, and a write-down of Rs. 18.35 crore on assets of the Sikkim manufacturing facility classified as held for sale under Ind AS 105.

4 For year ended 31st March 2026, consequent to the Finance Act amendment, the Company reassessed deferred tax assets and tax credits, and the resulting impact has been recognised as a credit in the Statement of Profit and Loss.

5 Disclosures as per Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable and additional informations are given hereunder:

Sr. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
a	**Debt-Equity Ratio (in times)** Debt / Net Worth [Debt : Total Debt (Short term + Long term) Net worth : Share Capital + Other Equity]	**0.25**	0.28	0.27	**0.25**	0.27	0.24
b	**Debt Service Coverage Ratio (in times)** (Profit before tax+interest) / (Interest + schedule principal repayments of Long term debt) Annualised	**10.99**	7.63	10.23	**9.55**	9.67	6.91
c	**Interest Service Coverage Ratio (in times)** (Profit before tax+interest)/ Interest	**12.45**	9.04	10.23	**11.02**	9.67	8.41
d	**Net Worth (Rs. in Crores)** (Equity capital + Other Equity excluding fair value change on financial Instruments through OCI)	**5,950.55**	5,856.21	5,322.35	**5,950.55**	5,322.35	5,680.88
e	**Current Ratio (in times)** Current Asset / Current Liabilities	**1.69**	1.69	1.59	**1.69**	1.59	1.75
f	**Long Term Debt to working capital (in times)** Long Term Borrowings (incl. Current Maturities)/ (Current Assets - Current Liabilities)	**0.05**	0.06	0.02	**0.05**	0.02	0.07
g	**Bad Debts to Accounts Receivable Ratio (%)** Bad Debts / Accounts Receivable	-	-	-	-	0.04%	0.07%
h	**Current Liability Ratio (in times)** Current Liabilities / Total Liabilities	**0.86**	0.85	0.89	**0.86**	0.89	0.84
i	**Total Debts to Total Assets (in times)** (Long term Borrowings + Short Term Borrowings+ Lease liability)/ Total Assets	**0.16**	0.18	0.18	**0.16**	0.18	0.16
j	**Debtors Turnover Ratio (in times)** (Value of Sales and Service / Average Debtor) Annualised	**6.11**	5.20	5.48	**5.59**	5.24	5.05
k	**Inventory Turnover (in times)** (Sale of products / Average WIP, FG and Stock in trade Inventory) Annualised	**5.90**	5.03	4.90	**5.40**	4.68	4.67
l	**Operating Margin (%)** EBITDA (before Exceptional items)/ Revenue from Operations	**22.21%**	16.18%	17.02%	**19.48%**	16.93%	16.03%
m	**Net Profit Margin (%)** (Net Profit after taxes and share of Profit/(Loss) of Associates and Joint Ventures)/ Revenue from Operations	**12.87%**	8.05%	9.67%	**10.69%**	9.36%	9.19%

For Alembic Pharmaceuticals Limited

Chirayu Amin
Chairman

Place : Vadodara
Date : 4th November,2026

Visit us at www.alembicpharmaceuticals.com

kkc & associates llp Chartered Accountants

Alembic Pharmaceuticals Limited

Statement of Assets and Liabilities - Consolidated

Rs. in Crores

	Particulars	As at 30th September, 2026 (Unaudited)	As at 31st March, 2026 (Audited)
A	**ASSETS**		
1	**Non-current assets**		
	(a) Property, plant and equipment	2,914.11	2,843.59
	(b) Capital work-in-progress	542.84	633.70
	(c) Other Intangible assets	327.83	237.08
	(d) Intangible assets under development	51.47	49.70
	(e) Financial Assets		
	(i) Investments	116.18	113.17
	(ii) Investment accounted for using Equity Method	36.42	27.71
	(f) Deferred tax assets (net)	260.62	269.61
	(g) Other non-current assets	28.58	15.43
2	**Current assets**		
	(a) Inventories	2,653.73	2,510.64
	(b) Financial Assets		
	- Trade receivables	1,896.15	1,466.30
	- Cash and cash equivalents	254.23	196.37
	- Bank balances other than cash and cash equivalents	7.54	6.33
	- Other financial assets	14.24	13.89
	(c) Current Tax Assets (Net)	20.88	10.68
	(d) Other current assets	375.86	338.38
	Assets classified as held for sale	30.00	30.00
	TOTAL - ASSETS	9,530.68	8,762.59
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
	(a) Equity Share capital	39.31	39.31
	(b) Other Equity	5,905.16	5,635.50
	Equity attributable to owners of the Company	5,944.47	5,674.81
	(c) Non-controlling interests	(7.87)	(5.83)
	Total Equity	5,936.60	5,668.98
2	**Non-current liabilities**		
	(a) Financial liabilities	90.52	121.92
	- Borrowings	31.56	44.76
	- Lease liabilities	165.86	152.91
	(b) Provisions	207.58	180.18
	(c) Other Non current Liability		
3	**Current liabilities**		
	(a) Financial liabilities	1,399.49	1,238.93
	- Borrowings	25.39	24.33
	- Lease liabilities		
	- Trade payables	64.00	59.77
	A) Due to Micro and Small Enterprises	1,095.08	775.31
	B) Due to other than Micro and Small Enterprises	170.18	278.54
	- Other financial liabilities	101.73	70.76
	(b) Other current liabilities	119.06	111.21
	(c) Provisions	123.63	34.98
	(d) Current Tax Liabilities (Net)		
	TOTAL - EQUITY AND LIABILITIES	9,530.68	8,762.59

For Alembic Pharmaceuticals Limited

Chirayu Amin
Chairman

Place : Vadodara
Date : 4th November,2026

Visit us at www.alembicpharmaceuticals.com

kkc & associates llp Chartered Accountants

Alembic Pharmaceuticals Limited

Consolidated Statement of Cash Flows For the half year ended 30th September, 2026

Rs. in Crores

Particulars	For the Half Year ended 30th September, 2026 (Unaudited)	for the Half year ended 30th September, 2025 (Unaudited)
A CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Profit Before Tax as per Statement of Profit and Loss (After Exceptional item)	659.81	413.82
Adjustments for:		
Share of (Profit) / Loss of Associates and Joint Ventures	0.98	(0.97)
Depreciation and amortisation	198.52	149.84
Interest Expense	65.86	47.75
Interest Income	(5.10)	(0.23)
Dividend Income / Gain on Sale of Investments	(0.77)	(0.19)
Unrealised foreign exchange (gain) / loss (net)	12.00	28.35
Fair value (gain)/ loss on financial instruments at fair value through profit or loss	(3.02)	(1.04)
Provision / write off for doubtful trade receivables	-	0.05
Sundry balances written off / written-back (net)	-	0.00
Loss/(Profit) on sale of Asset	0.09	1.89
Operating Profit before change in working capital	928.37	639.28
Working capital changes:		
(Increase) In Inventories	(143.08)	(252.56)
(Increase) In Trade Receivables	(487.49)	107.12
(Increase) In Other Assets	(31.05)	(34.68)
Increase In Trade Payables	326.39	3.47
Increase/(Decrease) In Other Liabilities	24.43	(20.22)
Increase/(Decrease) In Provisions	17.61	(5.17)
Cash generated from operations	635.18	437.25
Direct taxes paid (Net)	(63.80)	(34.33)
Net Cash inflow from Operating Activities (A)	571.38	402.92
B CASH FLOWS FROM INVESTING ACTIVITIES:		
Proceeds from Sale of Asset	0.05	-
Interest received	5.07	0.41
Dividend / Gain on Sale of Investments	0.77	0.19
Purchase of Property, Plant & Equipments and Capital Advance	(169.04)	(234.17)
Purchase of intangible assets (including intangible assets under Development)	(155.58)	(53.48)
Investment in Joint Venture	(9.60)	-
Net Cash inflow from Investing Activities (B)	(328.34)	(287.05)
C CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from long term borrowings	-	39.95
Net Proceeds / (Payments) in short term borrowings	127.65	178.45
Payment of lease liabilities	(14.98)	(12.29)
Change in Restricted Bank Balances other than Cash & Cash Equivalents	(0.85)	(2.22)
Dividends paid	(235.88)	(216.22)
Interest and other finance costs	(61.13)	(52.64)
Net Cash inflow from Financing Activities (C)	(185.19)	(64.97)
I Net (Decrease)/Increase in cash and cash equivalents (A+B+C)	57.86	50.90
II. Cash and cash equivalents at the beginning of the Year	196.37	83.48
III. Cash and cash equivalents at the end of the period (I+II)	254.23	134.38
IV. Cash and cash equivalents at the end of the period	254.03	134.14
Balances with Banks	0.20	0.23
Cash on hand	254.23	134.38
Cash and cash equivalents		

For Alembic Pharmaceuticals Limited

Chirayu Amin
Chairman

Place : Vadodara
Date : 4th November,2026

Visit us at www.alembicpharmaceuticals.com

kkc & associates llp Chartered Accountants

Independent Auditor's Review Report on unaudited consolidated financial results for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 of Alembic Pharmaceuticals Limited under Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Alembic Pharmaceuticals Limited

Introduction

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Alembic Pharmaceuticals Limited ('the Parent' or 'the Company') and its subsidiaries (the Parent and its subsidiaries together referred to as 'the Group') and its share of the net profit/(loss) after tax and total comprehensive income/(loss) of its associate for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). We have initialled the statement for identification purposes only.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Interim Financial Reporting' prescribed under section 133 of the Companies Act, 2013("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Scope of Review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ('the ICAI'). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular Issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

4. The Statement includes the interim financial results of entities mentioned in Annexure A.




Conclusion

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Ind AS specified under Section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

6. We did not review the interim financial result of 1 subsidiary included in the Statement, whose interim financial result, reflect total assets (before consolidation adjustment) of Rs.2,454.06 crore as at 30 September 2026, reflect total revenue (before consolidation adjustment) of Rs.1,084.70 crore and Rs.1,819.53 crore, total net (loss) after tax (before consolidation adjustment) of Rs.21.05 crore and Rs.46.99 crore, total comprehensive loss (before consolidation adjustment) of Rs.21.05 crore and of Rs. 46.99 crore, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and cash inflows (net) (before consolidation adjustment) of Rs. 40.85 crore for the period from 01 April 2026 to 30 September 2026 as considered in the Statement. This interim financial result has been reviewed by other auditor and their report, vide which they have issued an unmodified conclusion have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.


7. The Statement includes the interim financial results of 7 subsidiaries which have not been reviewed by their auditors, whose financial results reflect total assets (before consolidation adjustment) of Rs. 401.40 crore as at 30 September 2026, reflect total revenue (before consolidation adjustment) of Rs. 216.10 crore and Rs. 460.43 crore, total net loss (before consolidation adjustment) after tax of Rs. 13.84 crore and Rs. 5.62 crore, total comprehensive loss (before consolidation adjustment) of Rs. 13.84 crore and Rs. 5.62 crore for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and cash inflows (net) (before consolidation adjustment) of Rs. 33.02 Crore for the period from 01 April 2026 to 30 September 2026 as considered in the Statement. The Statement also includes the Group's share of net profit after tax (before consolidation adjustment) of Rs. 0.16 crore and Rs. 0.35 crore and total comprehensive income (before consolidation adjustment) of Rs. 0.16 crore and Rs. 0.35 crore for the quarter ended 30 September 2026 and for the period from 01 September 2026 to 30 September 2026 respectively, as considered in the Statement, in respect of 1 associate, based on their interim financial information / financial results which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information / financial results are not material to the Group.



8. The Parent Company's management has converted the interim financial results of 8 subsidiaries, which are located outside India, from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries is based on the review report of such other auditor and Management certified interim financial results as referred in above paras and the conversion adjustments prepared by the management of the Parent Company and reviewed by us.

   Our conclusion on the statement is not modified in respect of above matters.

For **KKC & Associates LLP**
Chartered Accountants
(formerly Khimji Kunverji & Co LLP)
Firm Registration Number: 105146W/W100621



Tejas Parikh
Partner
ICAI Membership No: 123215
UDIN: 26123215JDICMT4367

Place: Mumbai
Date: 04 November 2026

Sunshine Tower, Level 19, Senapati Bapat Marg, Elphinstone Road, Mumbai 400013, India
T: +91 22 6143 7333 E: info@kkcllp.in W: www.kkcllp.in LLPIN: AAP-2267

Suite 52, Bombay Mutual Building, Sir Phirozshah Mehta Road, Fort, Mumbai 400001, India

Annexure A

List of Entities :-

Sr.No	Name of Entity		Relation
1	Alembic Pharmaceuticals Limited		Parent
2	Alembic Pharmaceutical Inc.		Subsidiary
	a	Onkar Realty LLC [1]	Step down Subsidiary
	b	Alembic Labs LLC [2]	Step down Subsidiary
	c	Utility Therapeutics Limited [3]	Step down Subsidiary
	d	Alembic Therapeutics LLC [4]	Step down Subsidiary
3	Alembic Global Holding SA (AGH)		Subsidiary
	a	Alembic Pharmaceuticals Australia Pty Ltd	Step down Subsidiary
	b	Alembic Pharmaceuticals Canada Ltd	Step down Subsidiary
	c	Alembic Pharmaceuticals Europe Limited	Step down Subsidiary
	d	Genius LLC [5]	Step down Subsidiary
	e	Alnova Pharmaceuticals SA [6]	Step down Subsidiary
	f	TicTwo Therapeutics Inc.	Step down Subsidiary
	g	Alembic Lifesciences Inc.	Step down Subsidiary
	h	Rhizen Pharmaceuticals AG	Associate of AGH
	i	Dahlia Therapeutics SA [6]	Associate as a subsidiary of Rhizen Pharmaceuticals AG
	j	Alembic Mami SpA [7]	Joint venture
	k	SPH Sine Alembic (Shanghai) Pharmaceutical Technology Limited [8]	Joint Venture
	l	17989311 Canada Inc.[9]	Joint Venture
4	Alembic Pharmaceuticals Chile SpA		Subsidiary
5	Alembic Pharmaceuticals S.A.de C.V.		Subsidiary

kkc & associates llp Chartered Accountants

6	Alembic Pharmaceuticals Scientific Office L.L.C[10]	Subsidiary
7	Alembic Pharmaceuticals (Thailand) Ltd[11]	Subsidiary
8	Alembic Lifesciences Philippines Inc [12]	Subsidiary
9	Alembic Pharmaceuticals GmbH[13]	Subsidiary
10	Fenix Research Labs Private Limited [14]	Associate

[1] The entity was dissolved on 19 September 2024

[2] The entity was dissolved on 26 September 2024

[3] The entity has been acquired on 2 July 2025

[4] The entity has been incorporated on 19 March 2025

[5] Genius LLC is based out in Ukraine. The investment value in Genius LLC is already provided for by AGH during the F.Y.2022-2023. As at 30 September 2026, Genius LLC does not have any asset/liability, and no transaction is entered during the quarter ended 30 September 2026. As per Intimation 6 December 2024 to BSE Limited and National Stock Exchange of India limited by Parent company, this company has been non-operation and is in the process of dissolution.

[6] As per Intimation 6 December 2024 to BSE Limited and National Stock Exchange of India limited by Parent company, these company have been non-operation and is in the process of dissolution.

[7] The financial results of this entity have not been received or prepared by the Alembic Global Holding SA and no further share of loss is required to be borne by the Group as the entire Equity capital and loan given to it is fully provided for in earlier year. As per intimation dated 6 December 2024 to BSE Limited and National Stock Exchange of India Limited by Parent Company, this Company has been non-operational and is in the process of dissolution.

[8] The joint venture agreement was entered into on 7 May 2019. We are informed that the Group has invested Rs. 0.46 Crores and the operations have not started till 30 September 2026, and therefore, there are no transactions for the quarter ended 30 September 2026 and accordingly, no share of profit or loss has been consolidated in these interim financial results. This Joint Venture is in the process of product registration and will take due course of time for registration and commencement of operations.

[9] The entity was incorporated as joint venture on 3 June 2026

[10] Conversion from Branch to Subsidiary on 27 October 2025

[11] The entity has been incorporated on 6 March 2026

[12] The entity has been incorporated on 26 August 2026

[13] The entity has been incorporated on 21 April 2026

[14] Formerly known as Incozen Therapeutics Private Limited.

kkc & associates llp Chartered Accountants

ALEMBIC PHARMACEUTICALS LIMITED
CIN:L24230GJ2010PLC061123
Regd.Office: Alembic Road, Vadodara - 390 003
Tel : 0265 6637000
Email : apl.investors@alembic.co.in
Website : www.alembicpharmaceuticals.com

Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2026

Rs. in Crores

	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
1	**Revenue from Operations**	**2,391.65**	1,868.06	1,796.24	**4,259.72**	3,290.41	6,651.38
2	Other Income	**24.42**	14.04	11.49	**38.46**	19.29	55.90
3	**Total Income**	**2,416.07**	1,882.10	1,807.73	**4,298.17**	3,309.69	6,707.28
4	Expenses						
	(a) Cost of Materials consumed	**599.64**	517.30	463.14	**1,116.94**	894.41	1,747.38
	(b) Purchase of stock-in-trade	**134.24**	119.92	97.97	**254.16**	195.47	394.57
	(c) Changes in Inventories of finished goods, Stock in trade and WIP	**(30.26)**	(82.24)	22.80	**(112.50)**	(88.70)	(121.15)
	(d) Employee benefits expense	**454.20**	416.46	408.12	**870.66**	804.52	1,612.90
	(e) Finance Costs	**26.67**	21.41	22.81	**48.08**	45.45	86.51
	(f) Depreciation & Amortization Expense	**84.41**	82.54	75.64	**166.96**	149.01	311.00
	(g) Other Expenses	**612.36**	550.80	500.90	**1,163.16**	967.66	1,954.96
	Total Expenses	**1,881.26**	1,626.19	1,591.38	**3,507.46**	2,967.82	5,986.17
5	**Profit Before Exceptional Item and Tax**	**534.81**	255.90	216.35	**790.72**	341.87	721.10
6	Exceptional Item - Refer Note No. 2	**-**	-	-	**-**	-	(66.99)
7	**Profit Before Tax**	**534.81**	255.90	216.35	**790.72**	341.87	654.11
8	**Tax Expense**						
	(i) Current Tax	**96.00**	43.34	36.99	**139.34**	58.99	115.14
	(ii) Deferred Tax	**29.45**	15.61	-	**45.06**	-	(101.45)
9	**Profit for the Period**	**409.36**	196.96	179.36	**606.32**	282.88	640.42
10	**Other Comprehensive Income**						
	A (i) Items that will not be reclassified to profit / (loss)	**(2.69)**	(0.49)	(7.18)	**(3.18)**	(7.65)	(4.61)
	(ii) Income tax relating to items that will not be reclassified to profit / (loss)	**0.68**	0.12	1.25	**0.80**	1.34	0.93
	B (i) Items that will be reclassified to profit / (loss)	**(4.54)**	1.96	-	**(2.58)**	-	-
	(ii) Income tax relating to items that will be reclassified to profit/ (loss)	**1.14**	(0.49)	-	**0.65**	-	-
	Total Other Comprehensive Income (A+B)	**(5.41)**	1.09	(5.92)	**(4.31)**	(6.31)	(3.68)
11	**Total Comprehensive Income for the period**	**403.95**	198.06	173.44	**602.01**	276.57	636.74
12	Earnings per share - Basic & Diluted (in Rs.)	**20.83**	10.02	9.12	**30.85**	14.39	32.58
13	Paid up Equity Share Capital (Face Value of Rs 2/- each)	**39.31**	39.31	39.31	**39.31**	39.31	39.31
14	Other Equity						5,575.95

kkc & associates llp Chartered Accountants

Notes :

1 The above standalone results have been recommended by the Audit Committee and approved by the Board of Directors of the Company. The results have been subjected to review by the statutory auditors of the Company. The report of the statutory auditors is unqualified.

2 Exceptional items for the year ended 31st March 2026 comprised Rs. 48.64 crore relating to employee benefit obligations arising from the revised definition of wages under the Labour Codes, and a write-down of Rs. 18.35 crore on assets of the Sikkim manufacturing facility classified as held for sale under Ind AS 105.

3 For the year ended 31st March 2026, consequent to the Finance Act amendment, the Company reassessed deferred tax assets and tax credits, and the resulting impact has been recognised as a credit in the Statement of Profit and Loss.

4 Disclosures as per Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable and additional informations are given hereunder:

Sr. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
a	**Debt-Equity Ratio (in times)** Debt / Net Worth [Debt : Total Debt (Short term + Long term) Net worth : Share Capital + Other Equity]	0.19	0.22	0.25	0.19	0.25	0.20
b	Debt Service Coverage Ratio (in times) (Profit before tax+interest) / (interest + schedule principal repayments of Long term debt) Annualised	21.06	12.95	10.49	17.45	8.52	8.56
c	**Interest Service Coverage Ratio (in times)** (Profit before tax+interest)/ Interest	21.06	12.95	10.49	17.45	8.52	8.56
d	**Net Worth (Rs. in Crores)** (Equity capital + Other Equity excluding fair value change on financial Instruments through OCI)	5,987.47	5,819.40	5,258.15	5,987.47	5,258.15	5,621.34
e	**Current Ratio (in times)** Current Asset / Current Liabilities	1.85	1.75	1.59	1.85	1.59	1.70
f	**Bad Debts to Accounts Receivable Ratio (%)** Bad Debts/ Accounts Receivable	-	-	-	-	0.03%	0.03%
g	**Current Liability Ratio (in times)** Current Liabilities / Total Liabilities	0.93	0.94	0.95	0.93	0.95	0.93
h	**Total Debts to Total Assets (in times)** (Long term Borrowings + Short Term Borrowings+ Lease liability)/ Total Assets	0.13	0.15	0.18	0.13	0.18	0.15
i	**Debtors Turnover Ratio (in times)** (Value of Sales and Service / Average Debtor) Annualised	5.18	4.27	4.75	4.63	4.39	4.24
j	**Inventory Turnover (in times)** (Sale of products / Average WIP, FG and Stock in trade Inventory) Annualised	7.35	5.85	6.08	6.57	5.62	5.63
k	**Operating Margin (%)** EBITDA (before Exceptional items)/ Revenue from Operations	27.01%	19.26%	17.53%	23.61%	16.30%	16.82%
l	**Net Profit Margin (%)** Net Profit after taxes / Revenue from Operations	17.12%	10.54%	9.99%	14.23%	8.60%	9.63%

For Alembic Pharmaceuticals Limited

Chirayu Amin
Chairman

Place : Vadodara
Date : 4th November,2026

Visit us at www.alembicpharmaceuticals.com

kkc & associates llp Chartered Accountants

Alembic Pharmaceuticals Limited

Statement of Assets and Liabilities - Standalone

Rs. in Crores

	Particulars	As at 30th September, 2026 (Unaudited)	As at 31st March, 2026 (Audited)
A	**ASSETS**		
1	**Non-current assets**		
	(a) Property, plant and equipment	**2,893.00**	2,828.42
	(b) Capital work-in-progress	**542.84**	633.70
	(c) Intangible assets under development	**51.47**	49.70
	(d) Financial Assets		
	(i) Investments	**276.79**	271.40
	(ii) Loan	77.21	141.93
	(e) Deferred tax assets (net)	**135.40**	179.66
	(f) Other non-current assets	**28.58**	15.43
2	**Current assets**		
	(a) Inventories	**2,194.92**	2,048.16
	(b) Financial Assets		
	- Trade receivables	**2,032.98**	1,603.75
	- Cash and cash equivalents	**6.64**	22.67
	- Bank balances other than cash and cash equivalents	**7.27**	6.07
	- Loans	**65.54**	12.19
	- Others financial assets	**13.68**	13.40
	(c) Current Tax Assets (Net)	**0.03**	10.68
	(d) Other current assets	**328.04**	284.10
	Assets classified as held for sale	**30.00**	30.00
	TOTAL - ASSETS	**8,684.39**	8,151.25
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
	(a) Equity Share capital	**39.31**	39.31
	(b) Other Equity	**5,942.08**	5,575.95
2	**Non-current liabilities**		
	(a) Financial liabilities		
	- Lease liabilities	**17.77**	26.92
	(b) Provisions	**165.86**	152.91
3	**Current liabilities**		
	(a) Financial liabilities		
	- Borrowings	**1,111.50**	1,149.49
	- Lease liabilities	**19.83**	21.67
	- Trade payables		
	A) Due to Micro and Small Enterprises	**64.00**	59.77
	B) Due to other than Micro and Small Enterprises	**822.13**	600.93
	- Other financial liabilities	**166.17**	289.19
	(b) Other current liabilities	**98.79**	70.27
	(c) Provisions	**118.28**	110.42
	(d) Current Tax Liabilities (Net)	**118.67**	54.41
	TOTAL - EQUITY AND LIABILITIES	**8,684.39**	8,151.25

For Alembic Pharmaceuticals Limited

Chirayu Amin
Chairman

Place : Vadodara
Date : 4th November,2026

Visit us at www.alembicpharmaceuticals.com

kkc & associates llp Chartered Accountants

Alembic Pharmaceuticals Limited

Standalone Statement of Cash Flows For the half year ended 30th September, 2026

Rs. In Crores

Particulars	For the Half Year ended 30th September, 2026 (Unaudited)	for the Half year ended 30th September, 2025 (Unaudited)
A CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Profit Before Tax as per Statement of Profit and Loss (After Exceptional item)	**790.72**	341.87
Adjustments for:		
Depreciation and amortisation	**166.96**	149.01
Interest Expense	**48.08**	45.45
Interest Income	**(9.76)**	(3.26)
Dividend Income / Gain on Sale of Investments	**(0.77)**	(0.19)
Unrealised foreign exchange (gain) / loss (net)	**12.00**	28.35
Fair value (gain)/ loss on financial instruments at fair value through profit or loss	(3.02)	(1.04)
Provision / write off for doubtful trade receivables	-	0.05
Sundry balances written off / written-back (net)	-	0.00
Loss/(Profit) on sale of Asset	**0.09**	1.89
Operating Profit before change in working capital	1,004.29	562.14
Working capital changes:		
(Increase) In Inventories	**(146.76)**	(134.22)
(Increase)/Decrease In Trade Receivables	**(489.07)**	29.63
(Increase) In Other Assets	**(37.45)**	(31.51)
Increase In Trade Payables	**227.82**	(44.85)
Increase/(Decrease) In Other Liabilities	**20.59**	(20.75)
Increase/(Decrease) In Provisions	**17.62**	(5.12)
Cash generated from operations	597.04	355.33
Direct taxes paid (Net)	**(63.78)**	(23.07)
Net Cash inflow from Operating Activities (A)	533.26	332.26
B CASH FLOWS FROM INVESTING ACTIVITIES:		
Proceeds from Sale of Asset	**0.05**	-
Repayment of Loan by Subsidiary	**14.41**	(6.59)
Interest received	**6.01**	0.04
Dividend / Gain on Sale of Investments received	**0.77**	0.19
Purchase of Property, Plant & Equipment and Capital Advance	**(168.77)**	(233.32)
Purchase of intangible assets under Development	**(48.11)**	-
Payment towards purchase of investments	**(11.86)**	-
Investment in Subsidiary	**(2.37)**	(0.03)
Net Cash inflow from Investing Activities (B)	(209.87)	(239.71)
C CASH FLOWS FROM FINANCING ACTIVITIES:		
Net Proceeds / (Payments) in short term borrowings	**(37.99)**	195.78
Payment of lease liabilities	**(12.92)**	(11.43)
Increase in Restricted Bank Balances other than Cash & Cash Equivalents	**(0.85)**	(0.00)
Dividends paid	**(235.88)**	(216.22)
Interest and other finance costs	**(51.78)**	(51.93)
Net Cash inflow from Financing Activities (C)	(339.41)	(83.81)
I Net (Decrease)/Increase in cash and cash equivalents (A+B+C)	(16.02)	8.75
II. Cash and cash equivalents at the beginning of the Year	22.67	14.23
III. Cash and cash equivalents at the end of the period (I+II)	6.64	22.97
IV. Cash and cash equivalents at the end of the period		
Balances with Banks	**6.44**	22.74
Cash on hand	**0.20**	0.23
Cash and cash equivalents	6.64	22.97

For Alembic Pharmaceuticals Limited

Chirayu Amin
Chairman

Place : Vadodara
Date : 4th November,2026

Visit us at www.alembicpharmaceuticals.com

kkc & associates llp Chartered Accountants

Independent Auditor's Review Report on unaudited standalone financial results for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 of Alembic Pharmaceuticals Limited under Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Alembic Pharmaceuticals Limited

Introduction

1. We have reviewed the accompanying statement of unaudited standalone financial results of Alembic Pharmaceuticals Limited ('the Company') for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). We have initialled the statement for identification purposes only.

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Interim Financial Reporting' specified in section 133 of the Companies Act, 2013("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Scope of Review


3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India ('the ICAI'). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Conclusion

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS under Section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **KKC & Associates LLP**
Chartered Accountants
(formerly Khimji Kunverji & Co LLP)
Firm Registration Number: 105146W/W100621





Tejas Parikh
Partner
ICAI Membership No: 123215
UDIN: 26123215GLNFAJ4541

Place: Mumbai
Date: 04 November 2026

Sunshine Tower, Level 19, Senapati Bapat Marg, Elphinstone Road, Mumbai 400013, India
T: +91 22 6143 7333 E: info@kkcllp.in W: www.kkcllp.in LLPIN: AAP-2267

Suite 52, Bombay Mutual Building, Sir Phirozshah Mehta Road, Fort, Mumbai 400001, India